In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Introduction to the EuroPCR 2010 Program

William Wijns, Chairman of EuroPCR

With only few days before our gathering in Paris, let me give you a few hints regarding the scientific program of EuroPCR 2010.

Read below which are in my opinion, the Top 5 New Key Features of EuroPCR 2010.

  • Your input and suggestions are the foundations on which the entire program was built. More than ever in the past, we have engaged the constituents of our Association: national interventional Working Groups, Program Committee Members, individual attendees. Their input was obtained through a series of Calls for Submission, starting in September 2009 up to the final call for Late Breaking Trial presentations.
    Thus YOU have submitted and selected the main themes for this year: the clinical cases, the complication cases, the How should I treat sessions, …
    In this way, we can all learn for our cumulative, shared experience.

  • Innovation will be highlighted in many ways. Of course through the classical Glimpse into the Future sessions and the various Hot Line presentations, but new session formats will be introduced as well. Be prepared for some surprises … especially on Wednesday 26 May…

  • With so many concurrent events, attendees may find it difficult to identify “the” not to be missed sessions that address exactly their needs. To help you in building your schedule, you will notice that all sessions in the Coronary, Valvular and Structural Heart Disease programs have been given a TAG depending on their main focus: Innovation, Technique, Clinic, Evidence.
    These tags mirror the life-cycle of a successful therapy, moving from innovation through the technical application, on to clinical studies, and finally evidence that turns into guidelines and changes in practice. Look for these tags, they are your Gateways to a fruitful participation in the Course.

  • The Peripheral program has been completely re-engineered as to target interventional cardiologists. Sessions will address both the basics and more advanced practice of peripheral interventions. Sessions are clearly labeled as such to help you building your schedule.

  • Last but not least, further to last year’s turning point, a growing part of the meeting will be devoted to the presentation of abstracted reports on innovation and science in the field of Percutaneous Cardiovascular Interventions. The number of submissions has reached 701, a 24% increase compared to 2009. We are tremendously grateful to the 52 reviewers and graders (+14 from 2009) who donated their time and provided thorough and objective review. We acknowledge the great contribution of the EAPCI leadership and the EAPCI Scientific Program Committee chaired by D. Dudek and M. Roffi. Out of 55 oral abstract presentation sessions (+9 from 2009), we will have 40 on coronary interventions, 7 on structural and valvular heart disease, 7 on peripheral interventions.
    Lastly, every EuroPCR has to feature a number of first times! In 2010, one of the first times will be the introduction of Poster sessions. Up to 100 posters will be displayed and we invite you to attend the interactive sessions with the presenters that are scheduled on Wednesday May 26 and Thursday 27 May (from 12:00 to 13:30).

Hoping you will find these tips useful when going through the interactive program, I would like to wish you a very gratifying week in Paris.

Dr William Wijns
Chairman of EuroPCR